HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (38) Citing Articles via Google Scholar Google Scholar Articles by Tammemagi, C. M. Articles by Kvale, P. Search for Related Content PubMed PubMed Citation Articles by Tammemagi, C. M. Articles by Kvale, P.

Smoking and Lung Cancer Survival^*

The Role of Comorbidity and Treatment

^* From the Josephine Ford Cancer Center (Dr. Tammemagi and Ms. Neslund-Dudas); and Pulmonary Critical Care Medicine (Drs. Simoff and Kvale), Henry Ford Health System, Detroit, MI.

Correspondence to: C. Martin Tammemagi, PhD, Josephine Ford Cancer Center, 1 Ford Place, 5C, Detroit, MI 48202-3450; e-mail: mtammem1{at}hfhs.org

Study objectives: Numerous studies indicate that smoking is associated with poorer outcomes in patients with cancer. The aim of this study was to determine whether smoking independently predicts survival in patients with lung cancer or whether an existent effect is mediated through comorbidity and/or treatment.

Design and setting: Cox proportional hazards analysis was used to study a cohort of 1,155 patients with lung cancer diagnosed at the Henry Ford Health System between 1995 and 1998, inclusive.

Results: Adjusted for the baseline covariates, age, gender, illicit drug use, adverse symptoms, histology, and stage, the hazard ratio (HR) for smoking (current vs former/never) was 1.37 (95% confidence interval [CI], 1.18 to 1.59; p < 0.001). Adjusted for the baseline covariates and for 18 deleterious comorbidities, the HR for smoking was 1.38 (95% CI, 1.18 to 1.60; p < 0.001), indicating that the hazardous effect of smoking was not mediated through comorbidity. Current smoking was inversely associated with treatment (any surgery and/or chemotherapy and/or radiation therapy vs none) [odds ratio, 0.73; 95% CI, 0.55 to 0.98 (p = 0.03)]. Adjusted for baseline covariates, comorbidities and treatment, the HR for current smoker vs former/never was 1.26 (95% CI, 1.08 to 1.47; p = 0.003), a decline of 30.7% explained by treatment (HR for any treatment vs none, 0.40; 95% CI, 0.33 to 0.48; p < 0.001).

Conclusions: Current smoking at diagnosis is an important independent predictor of shortened lung cancer survival. That this effect was not explained by sociodemographic/exposure factors, adverse symptoms, histology, stage, comorbidity, and treatment suggests that it may be mediated through direct biological effects.

Key Words: comorbidity • lung neoplasm • smoking • survival • symptoms • treatment

This article has been cited by other articles:

				C.-K. Toh, F. Gao, W.-T. Lim, S.-S. Leong, K.-W. Fong, S.-P. Yap, A. A.L. Hsu, P. Eng, H.-N. Koong, A. Thirugnanam, et al. Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity J. Clin. Oncol., May 20, 2006; 24(15): 2245 - 2251. [Abstract] [Full Text] [PDF]

				G. J. Riely, W. Pao, D. Pham, A. R. Li, N. Rizvi, E. S. Venkatraman, M. F. Zakowski, M. G. Kris, M. Ladanyi, and V. A. Miller Clinical Course of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib Clin. Cancer Res., February 1, 2006; 12(3): 839 - 844. [Abstract] [Full Text] [PDF]

				E. R. Gritz, C. Dresler, and L. Sarna Smoking, The Missing Drug Interaction in Clinical Trials: Ignoring the Obvious Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2287 - 2293. [Abstract] [Full Text] [PDF]

				T.-Y. Chou, C.-H. Chiu, L.-H. Li, C.-Y. Hsiao, C.-Y. Tzen, K.-T. Chang, Y.-M. Chen, R.-P. Perng, S.-F. Tsai, and C.-M. Tsai Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3750 - 3757. [Abstract] [Full Text] [PDF]

				P. J. Mazzone and A. C. Arroliga How Many Ways Can We Say That Cigarette Smoking Is Bad for You? Chest, December 1, 2004; 126(6): 1717 - 1718. [Full Text] [PDF]

				Y. I. Garces, P. Yang, J. Parkinson, X. Zhao, J. A. Wampfler, J. O. Ebbert, and J. A. Sloan The Relationship Between Cigarette Smoking and Quality of Life After Lung Cancer Diagnosis Chest, December 1, 2004; 126(6): 1733 - 1741. [Abstract] [Full Text] [PDF]

				P. J. Mazzone, T. Mekhail, and A. C. Arroliga Is Lung Cancer in the Nonsmoker a Different Disease? Chest, August 1, 2004; 126(2): 326 - 329. [Full Text] [PDF]